New Technology to Increase Efficacy of Adult Stem Cells in COPD Treatment
Entest BioMedical announced today it has filed a second patent application in the area of Chronic Obstructive Pulmonary Disease (COPD). This new patent application builds upon the Company’s previously filed COPD patent application and involves the use of photoceutical devices to target stem cells toward areas impacted by COPD in the lungs.
Steve Josephs, PhD, a Scientific Advisor to the Company stated “that by using photoceutical devices in treating COPD, it is believed stem cells can be focused on areas of the lungs where there is damage. Furthermore, being
Biological sciences major Adam Reese may have found the key to keep fat cells from forming.
The University of Delaware junior believes he has identified the trigger that turns a stem cell into a fat cell. Located on the surface of cells, the trigger — a protein called endoglin — regulates what type of cell an existing stem cell will become.
Working in the UD Department of Biological Sciences‘ laboratory of cellular signaling and dynamics with assistant professor Anja Nohe, Reese investigates ways to combat osteoporosis. His findings may also have implications for obesity.
Patients afflicted with osteoporosis lose bone mass as
Stem cells extracted from body fat may pave the way for the development of new regenerative therapies including soft tissue reconstruction following tumor removal or breast mastectomy surgery, the development of tissue-engineered cartilage or bone, and the treatment of cardiovascular disease.
An interdisciplinary team of Queen’s University researchers led by Dr. Lauren Flynn, a professor in the Departments of Chemical Engineering and Anatomy and Cell Biology, has been working with stem cells extracted from samples of human fat and is developing new methods in the lab to develop these cells into mature tissue substitutes.
While stem cells extracted from fat cannot
IntelliCell BioSciences filed its patent application with the US Patent office that will claim priority to its provisional US patent serial #61/427, 221 that was filed on December 27, 2010. The title of the patent application is Ultrasonic Cavitation Derived Stromal or Mesenchymal Vascular Extracts and Cells Derived Therefrom Obtained from Adipose Tissue and use Thereof. It covers the methods of manufacturing using ultrasonic cavitation to dissociate the fat cells and blood vessels contained within the adipose tissue, thereby obtaining multi-potent, mesenchymal or stromal vascular fractions for use in human subjects. These methods do not include the use of
Life Stem Genetics announced today a strategic collaborative agreement with American CryoStem Corporation.
CRYO is a leading developer, marketer and global licensor of patented adipose tissue-based cellular technologies for the Regenerative and Personalized Medicine industries.
Adipose tissue is an anatomical term for loose connective tissue (fat) composed of adipocytes (cells). It is used in LIFS stem cell procedures and currently is extracted via liposuction each time a patient has a treatment.